FAVONI, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 1.816
EU - Europa 977
AS - Asia 658
AF - Africa 68
SA - Sud America 4
OC - Oceania 2
Totale 3.525
Nazione #
US - Stati Uniti d'America 1.810
SG - Singapore 242
GB - Regno Unito 241
IT - Italia 199
CN - Cina 196
DE - Germania 157
SE - Svezia 154
IN - India 74
VN - Vietnam 55
IE - Irlanda 52
JO - Giordania 39
RU - Federazione Russa 37
FR - Francia 30
BG - Bulgaria 27
NG - Nigeria 25
ZA - Sudafrica 22
UA - Ucraina 18
PK - Pakistan 16
FI - Finlandia 14
EE - Estonia 13
AT - Austria 12
TG - Togo 10
CI - Costa d'Avorio 9
ID - Indonesia 8
CA - Canada 6
TH - Thailandia 6
BE - Belgio 5
NL - Olanda 5
HK - Hong Kong 4
JP - Giappone 4
CH - Svizzera 3
IL - Israele 3
UZ - Uzbekistan 3
BR - Brasile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
IR - Iran 2
KR - Corea 2
LB - Libano 2
QA - Qatar 2
RO - Romania 2
SC - Seychelles 2
AR - Argentina 1
AU - Australia 1
BY - Bielorussia 1
CL - Cile 1
HR - Croazia 1
LT - Lituania 1
NZ - Nuova Zelanda 1
PL - Polonia 1
Totale 3.525
Città #
Southend 227
Singapore 220
Fairfield 213
Santa Clara 160
Woodbridge 122
Ashburn 116
Chandler 112
Houston 103
Seattle 92
Ann Arbor 91
Princeton 80
Wilmington 80
Cambridge 78
Boardman 56
Dublin 52
Amman 39
Turin 39
Bologna 29
Sofia 27
Abeokuta 25
Redmond 25
Westminster 23
Dong Ket 22
San Diego 21
Berlin 20
Chengdu 18
Nanjing 15
Des Moines 14
Monzuno 14
Helsinki 10
Lomé 10
Saint Petersburg 10
Abidjan 9
Hebei 9
Nanchang 9
Padova 9
Shenyang 9
Beijing 8
Guangzhou 8
Jakarta 8
New York 8
Shanghai 8
Dearborn 7
Jacksonville 7
Jiaxing 7
Jinan 7
Milan 7
Muzaffargarh 7
Redwood City 7
Hyderabad 6
Olalla 6
Vienna 6
Bangkok 5
Brussels 5
Changsha 5
Imola 5
Los Angeles 5
Phoenix 5
Tianjin 5
Chicago 4
Costa Mesa 4
Florence 4
Gujranwala 4
Hangzhou 4
Hong Kong 4
Lappeenranta 4
Pianoro 4
Shenzhen 4
Wuhan 4
Amsterdam 3
Bühl 3
Mülheim 3
Ningbo 3
Norwalk 3
Parma 3
San Mateo 3
Seriate 3
Silvi 3
Taiyuan 3
Washington 3
Zhengzhou 3
Atlanta 2
Bremen 2
Brno 2
Chongqing 2
Council Bluffs 2
Doha 2
Edmonton 2
Falkenstein 2
Falls Church 2
Frankfurt Am Main 2
Frankfurt am Main 2
Groningen 2
Haikou 2
Harbin 2
Hefei 2
Lanzhou 2
Lucerne 2
Mahé 2
Monterotondo 2
Totale 2.464
Nome #
Cerebrospinal fluid hypocretin-1 levels during the active period of cluster headache. 135
Idiopathic intracranial hypertension without papilledema (IIHWOP) in chronic refractory headache 135
Treatment of withdrawal headache in patients with medication overuse headache: a pilot study 134
Migraine and sleep disorders. 122
A real-world study on unmet medical needs in triptan-treated migraine: Prevalence, preventive therapies and triptan use modification from a large Italian population along two years 122
Interobserver reliability of ICSD-3 diagnostic criteria for disorders of arousal in adults 122
Greater Occipital Nerve Infiltration During Pregnancy in Cluster Headache: A Case Report 118
Vessel-wall MRI in primary headaches: The role of neurogenic inflammation 111
Superficial siderosis associated with peripheral autonomic failure and tetraventricular hydrocephalus: a case report 104
Clinical and radiological prognostic factors in spontaneous intracranial hypotension: a case series 102
Transverse Sinus Stenosis in Refractory Chronic Headache Patients: An Observational Study 100
The incidental finding of elevated anti GQ1B antibodies in a patient with selective small fiber neuropathy 99
Migraine and cardiovascular diseases. 98
CGRP and migraine from a cardiovascular point of view: What do we expect from blocking CGRP? 97
SUNCT/SUNA and neurovascular compression: New cases and critical literature review. 96
SPARTACUS: underdiagnosis of chronic daily headache in primary care. 96
Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording 95
Quality indicators in headache care: an implementation study in six Italian specialist-care centres 93
Recurrent Reversible Cognitive Impairment in a Cluster Headache Patient: A Case Report 89
Rare primary headaches in Italian tertiary Headache Centres: Three year nationwide retrospective data from the RegistRare Network 89
Nociception and autonomic nervous system. 87
Energy Metabolism Impairment in Migraine 87
State and trait anger and its expression in cluster headache compared with migraine: a cross-sectional study 86
null 80
Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache 78
Erenumab efficacy in highly resistant chronic migraine: a real-life study 76
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache 73
Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network 70
Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center 70
Great occipital nerve long-acting steroid injections in cluster headache therapy: an observational prospective study 70
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) 66
Vessel-wall MRI in thunderclap headache: A useful tool to answer the riddle? 63
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) 58
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study 56
P063. Colloid cysts of the third ventricle: a case report 54
Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs 54
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic 44
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 43
Migraine chronification as an allostatic disorder: a proof-of-concept study 30
Is physiotherapy in migraines known to sufferers? A cross-sectional study 23
Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: a real-world prospective study 23
Greater occipital nerve blockade in cluster headache: effectiveness and safety of a combined injection protocol 23
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study 22
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study 21
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance 16
Central and Peripheral Nervous Disorders 16
An unusual case of anti-basal ganglia encephalitis showing polyradiculoneuritis features 13
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study 13
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data 11
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study 10
The ultimate guide to the anti-CGRP monoclonal antibodies galaxy 8
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience 8
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study 7
Moving closer to the ideal migraine acute treatment 7
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men 7
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study 6
Totale 3.636
Categoria #
all - tutte 11.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.186


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020561 0 0 0 0 0 78 95 116 136 46 47 43
2020/2021399 91 27 4 17 18 11 14 29 60 25 18 85
2021/2022635 37 16 41 31 63 20 13 85 21 75 142 91
2022/2023681 64 69 23 81 67 43 38 38 144 29 65 20
2023/2024290 10 42 23 47 11 51 24 19 8 29 9 17
2024/2025729 50 239 90 71 220 59 0 0 0 0 0 0
Totale 3.636